The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Efficacy of mosunetuzumab monotherapy in elderly/unfit patients with previously untreated DLBCL
Adam Olszewski, MD, Brown University, Providence, RI, discusses a Phase Ib/II trial evaluating the safety and efficacy of mosunetuzumab in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma (DLBCL; NCT03677154). Results demonstrated that mosunetuzumab was well tolerated in this patient population, with low grade cytokine release syndrome (CRS) being the main adverse event (AE) experienced by patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Adaptive Biotechnologies and Genentech: Research Funding; Genmab, Schrodinger, Blue Cross and Blue Shield of Rhode Island and TG Therapeutics: Consultancy; Brown Physicians, Inc.: Current Employment.
